Full Text View
Tabular View
Study Results
Related Studies
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
This study has been completed.
Study NCT01152554   Information provided by AstraZeneca

First Received on June 28, 2010.   Last Updated on September 27, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Major Depressive Disorder
MDD
Depression
Additional conditions recognized in this trial
Depressive Disorder
Depressive Disorder, Major
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Interventions listed in this trial
TC-5214
Placebo
Additional drug interventions recognized in this trial
Antidepressive Agents
Serotonin Uptake Inhibitors
More general drug interventions related to this trial
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca
Targacept Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services